Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms
暂无分享,去创建一个
Dexin Kong | Meihua Jin | T. Yamori | Dexin Kong | Yanwen Zhang | Takao Yamori | Hongquan Duan | Meihua Jin | Hongquan Duan | Yanwen Zhang
[1] Alice T. Loo,et al. PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.
[2] Dexin Kong,et al. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. , 2009, Biological & pharmaceutical bulletin.
[3] K. Kobashi,et al. Balicalin, the Predominant Flavone Glucuronide of Scutellariae Radix, is Absorbed from the Rat Gastrointestinal Tract as the Aglycone and Restored to its Original Form , 2000, The Journal of pharmacy and pharmacology.
[4] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[5] D Kromhout,et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. , 1995, Archives of internal medicine.
[6] S. Dan,et al. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. , 2010, European journal of cancer.
[7] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[8] S. Hirono,et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.
[9] C. Kandaswami,et al. The antitumor activities of flavonoids. , 2005, In vivo.
[10] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[11] A. Toker,et al. Signalling through the lipid products of phosphoinositide-3-OH kinase , 1997, Nature.
[12] Dexin Kong,et al. Advances in development of phosphatidylinositol 3-kinase inhibitors. , 2009, Current medicinal chemistry.
[13] A. Robertson,et al. PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.
[14] C. Rommel,et al. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? , 2007, Nature reviews. Immunology.
[15] C. Edwards,et al. Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. , 2000, Biological research.
[16] A. Aro,et al. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. , 2001, The Journal of nutrition.
[17] Dexin Kong,et al. ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms , 2007, Cancer science.
[18] R. Copeland,et al. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. , 2011, Biochemical and biophysical research communications.
[19] Dexin Kong,et al. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. , 2009, European journal of cancer.
[20] A. Robertson,et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. , 2005, Nature medicine.
[21] Dexin Kong,et al. Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy , 2008, Cancer science.
[22] Dexin Kong,et al. Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library. , 2010, Biological & pharmaceutical bulletin.
[23] E. Middleton. Effect of plant flavonoids on immune and inflammatory cell function. , 1998, Advances in experimental medicine and biology.
[24] M. R. Peluso. Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver , 2006, Experimental biology and medicine.